Moxidectin Elevates Ergosterol to Potentiate Polyene Antifungals Against Candida albicans

Study Background and Research Question

Candida albicans is a leading cause of oral candidiasis, particularly affecting immunocompromised individuals, the elderly, and children. The rise in oral candidiasis is driven by factors such as increased antibiotic use, immune-modulating therapies, and higher prevalence of diabetes or HIV. Despite the longstanding clinical use of polyene antifungals—most notably amphotericin B and nystatin—their utility is limited by toxicity, low solubility, and mounting drug resistance. The urgent need for novel or synergistic antifungal strategies forms the backdrop of recent research exploring drug repurposing and combination therapies.

Moxidectin, a macrocyclic lactone anthelmintic traditionally used for parasitic worm control in both veterinary and, more recently, human medicine, has been considered for its unexpected antifungal potential. The central research question addressed in the reference study is whether moxidectin can modulate fungal ergosterol biosynthesis to enhance the efficacy of polyene antifungals against C. albicans and its clinical isolates, and what mechanistic basis underlies such synergy.

Key Innovation from the Reference Study

The principal innovation reported by Ye et al. (2024) lies in demonstrating that moxidectin can upregulate ergosterol biosynthesis in C. albicans, thereby increasing the polyenes’ binding target and amplifying their fungicidal effect. This mechanism is distinct from moxidectin's established role in parasitic worm control, where it acts on glutamate-gated chloride channels. The study is the first to show that a macrocyclic lactone anthelmintic can act as a potentiator for polyene antifungals via direct modulation of ergosterol content in fungal cells—a novel cross-domain strategy with potential to improve oral candidiasis treatment outcomes.

Methods and Experimental Design Insights

The research team employed a multi-pronged experimental approach:

• In vitro synergy assays: Minimum inhibitory concentration (MIC) and checkerboard assays evaluated the combined effects of moxidectin with amphotericin B (AmB) and nystatin (Nys) on C. albicans SC5314 and 60 clinical isolates.
• Biofilm inhibition: Combination treatments were tested for their ability to disrupt biofilm formation—a key virulence factor in oral candidiasis.
• Transcriptome and RT-PCR: These analyses identified changes in gene expression, focusing on the ergosterol biosynthetic pathway.
• Mutant strain validation: Synergy was assessed in ergosterol pathway mutants (Δ/Δerg3, Δ/Δerg11, Δ/Δerg3 Δ/Δerg11) to confirm the mechanistic link between moxidectin, ergosterol, and polyene action.
• Biochemical quantification: Ergosterol content was directly measured in treated cells.
• In vivo efficacy: A mouse model of oral candidiasis was used to assess clinical relevance, including infection area, fungal burden, and mucosal inflammation after combination therapy.

Core Findings and Why They Matter

The study’s findings are multifaceted and have notable clinical and mechanistic implications:

• Synergy with Polyenes: Moxidectin significantly decreased the MICs of both amphotericin B and nystatin against C. albicans strains, indicating true pharmacological synergy (Ye et al., 2024).
• Biofilm Inhibition: The combination therapies were more effective at inhibiting biofilm formation than either drug alone, targeting a key contributor to persistent infection.
• Mechanistic Confirmation: Transcriptome profiling and RT-PCR showed that moxidectin upregulated genes in the ergosterol biosynthesis pathway. Loss of synergy in ergosterol biosynthetic mutants confirmed that elevated ergosterol is essential for enhanced polyene activity.
• Ergosterol Quantification: Direct measurement confirmed that moxidectin treatment increased cellular ergosterol levels, directly enhancing the target for polyene binding.
• In Vivo Validation: In a mouse oral candidiasis model, moxidectin-polyene combinations reduced infection area, fungal colonization, and local inflammation more effectively than monotherapies.

This evidence positions moxidectin as a rational adjunct to existing polyene antifungals, especially relevant for cases where resistance or host toxicity limits conventional dosing. The identification of ergosterol biosynthesis modulation as a synergy mechanism is a critical advance for antifungal pharmacology.

Comparison with Existing Internal Articles

Several recent reviews and research-focused articles support and contextualize these findings. For instance, the article "Moxidectin: Bridging Antiparasitic and Antifungal Frontiers" discusses the emerging role of moxidectin, emphasizing cross-domain innovation and mechanistic insight regarding ergosterol-mediated synergy. Similarly, "Moxidectin: Macrocyclic Lactone Anthelmintic in Antifungal Synergy" provides protocol guidance for leveraging high-purity moxidectin in laboratory workflows.

These internal resources expand upon the reference study by offering troubleshooting advice, practical workflow suggestions, and detailed consideration of moxidectin’s physicochemical properties—such as solubility in ethanol and DMSO—which are essential for assay setup and compound handling. Collectively, they reinforce the translational potential of combining moxidectin with polyene antifungals and highlight vendor-specific quality control considerations relevant to experimental reproducibility.

Protocol Parameters

• Synergy testing: Use checkerboard assays with clinical and reference isolates; start with moxidectin concentrations ranging from sub-MIC to low micromolar levels alongside standard polyene dosing.
• Biofilm assays: Quantify biofilm biomass after 24–48 hours of combined drug exposure; compare against single-agent controls.
• Gene expression profiling: After 4–6 hours of moxidectin exposure, extract RNA for RT-PCR or transcriptome analysis targeting ergosterol pathway genes (e.g., ERG3, ERG11).
• Mutant validation: Employ ergosterol pathway knockout strains to confirm mechanistic dependence on ergosterol upregulation.
• In vivo dosing: For mouse oral candidiasis models, administer moxidectin and polyene combinations at doses scaled from in vitro synergy thresholds; monitor infection area and inflammatory markers.
• Compound handling: Prepare moxidectin stock solutions in ethanol or DMSO (≥128 mg/mL and ≥129.4 mg/mL, respectively); warm gently or use ultrasonic assistance if needed for complete dissolution.
• Storage conditions: Store moxidectin at -20°C; avoid long-term storage of solutions and use promptly after preparation, as recommended by the product information.

Limitations and Transferability

Despite the promising preclinical results, several limitations must be considered before generalizing these findings. First, the in vivo data are limited to a mouse model of oral candidiasis and may not fully capture the pharmacokinetic and safety profiles required for clinical translation in humans. The specificity of moxidectin’s ergosterol-elevating effect to C. albicans (versus other fungal species) remains to be thoroughly explored. Additionally, while the synergy mechanism is robustly supported by mutant analysis, off-target effects and the broader impact on host microbiota or immune function require further investigation.

The translational potential is also modulated by regulatory considerations, as moxidectin is primarily approved as a veterinary antiparasitic and only recently as an FDA-approved anthelmintic for onchocerciasis in humans. Dose optimization, safety, and efficacy must be validated in clinical trials for antifungal indications.

Why this cross-domain matters, maturity, and limitations

The cross-domain use of a macrocyclic lactone anthelmintic to potentiate antifungal therapy exemplifies the value of drug repurposing, particularly in areas of unmet clinical need such as antifungal resistance. The mechanistic insight—ergosterol biosynthesis upregulation—provides a rational basis for combination therapy and may inform the development of new adjunctive regimens for recalcitrant oral candidiasis. However, the maturity of this approach remains preclinical, and careful attention to dosing, toxicity, and regulatory status will be critical in future translational work.

Research Support Resources

For researchers aiming to replicate or extend these findings, high-purity Moxidectin (SKU B3611) is available for laboratory use. Provided with thorough quality control data and solubility guidance, this resource supports precise dosing and reproducible assay setup for synergy and mechanistic studies. Consult the product documentation for detailed storage and handling recommendations to maintain compound integrity in experimental workflows.